Cargando…

Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α

BACKGROUND: Inflammation represents an early and key event in the development of both the cutaneous psoriasis and psoriatic arthritis. Compelling evidences indicate that the production of TNF-α plays a central role in psoriasis by sustaining the inflammatory process in the skin as well as in the joi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordiali-Fei, Paola, Trento, Elisabetta, D'Agosto, Giovanna, Bordignon, Valentina, Mussi, Anna, Ardigò, Marco, Mastroianni, Antonio, Vento, Antonella, Solivetti, Francesco, Berardesca, Enzo, Ensoli, Fabrizio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1601955/
https://www.ncbi.nlm.nih.gov/pubmed/17022813
http://dx.doi.org/10.1186/1740-2557-3-5
_version_ 1782130449785552896
author Cordiali-Fei, Paola
Trento, Elisabetta
D'Agosto, Giovanna
Bordignon, Valentina
Mussi, Anna
Ardigò, Marco
Mastroianni, Antonio
Vento, Antonella
Solivetti, Francesco
Berardesca, Enzo
Ensoli, Fabrizio
author_facet Cordiali-Fei, Paola
Trento, Elisabetta
D'Agosto, Giovanna
Bordignon, Valentina
Mussi, Anna
Ardigò, Marco
Mastroianni, Antonio
Vento, Antonella
Solivetti, Francesco
Berardesca, Enzo
Ensoli, Fabrizio
author_sort Cordiali-Fei, Paola
collection PubMed
description BACKGROUND: Inflammation represents an early and key event in the development of both the cutaneous psoriasis and psoriatic arthritis. Compelling evidences indicate that the production of TNF-α plays a central role in psoriasis by sustaining the inflammatory process in the skin as well as in the joints. Among the multiple effects produced by TNF-α on keratinocytes, the induction of matrix metalloproteinase-9 (MMP-9), a collagenase implicated in joint inflammatory arthritis which acts as an angiogenesis promoting factor, might represent a key mechanism in the pathogenesis of the disease. Aims of the present study were to investigate a) the role of MMP-9 in the development of psoriasis by assessing the presence of MMP-9 in lesional skin and in sera of psoriatic patients; b) the association of MMP-9 with the activity of the disease; c) the relationship between MMP-9 and TNF-α production. METHODS: Eleven psoriatic patients, clinically presenting joint symptoms associated to the cutaneous disease, were included in a therapeutic protocol based on the administration of anti-TNF-α monoclonal antibody (Infliximab). Sera and skin biopsies were collected before treatment and after 6 weeks of therapy. Tissues were kept in short term cultures and production soluble mediators such as TNF-α, MMP-9, MMP-2, VEGF and E-Selectin, which include angiogenic molecules associated to the development of plaque psoriasis, were measured in the culture supernatants by immunoenzymatic assays (ng/ml or pg/ml per mg of tissue). MMP-9 concentrations were also measured in the sera. The cutaneous activity of disease was evaluated by the Psoriasis Area and Severity Index (PASI). RESULTS: Clinical and laboratory assessment indicated that all but one patients had a significant improvement of the PASI score after three months of therapy. The clinical amelioration was associated to a significant decrease of MMP-9 (P = 0.017), TNF-α (P = 0.005) and E-selectin (P = 0.018) levels, spontaneously released by lesional biopsies before and after therapy. In addition, significant correlations were found between the PASI measurements and TNF-α (r(2 )= 0.33, P = 0.005), MMP-9 (r(2 )= 0.25, P = 0.017), E-selectin (r(2 )= 0.24, P = 0.018) production. MMP-9 levels were significantly correlated with those of TNF-α (r(2 )= 0.30, P = 0.008). A significant decrease of MMP-9 in the sera, associated to the clinical improvement was also found. CONCLUSION: Our findings show the existence of a direct relationship between MMP-9 and TNF-α production strongly suggesting that MMP-9 may play a key role in the skin inflammatory process in psoriasis.
format Text
id pubmed-1601955
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-16019552006-10-13 Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α Cordiali-Fei, Paola Trento, Elisabetta D'Agosto, Giovanna Bordignon, Valentina Mussi, Anna Ardigò, Marco Mastroianni, Antonio Vento, Antonella Solivetti, Francesco Berardesca, Enzo Ensoli, Fabrizio J Autoimmune Dis Research BACKGROUND: Inflammation represents an early and key event in the development of both the cutaneous psoriasis and psoriatic arthritis. Compelling evidences indicate that the production of TNF-α plays a central role in psoriasis by sustaining the inflammatory process in the skin as well as in the joints. Among the multiple effects produced by TNF-α on keratinocytes, the induction of matrix metalloproteinase-9 (MMP-9), a collagenase implicated in joint inflammatory arthritis which acts as an angiogenesis promoting factor, might represent a key mechanism in the pathogenesis of the disease. Aims of the present study were to investigate a) the role of MMP-9 in the development of psoriasis by assessing the presence of MMP-9 in lesional skin and in sera of psoriatic patients; b) the association of MMP-9 with the activity of the disease; c) the relationship between MMP-9 and TNF-α production. METHODS: Eleven psoriatic patients, clinically presenting joint symptoms associated to the cutaneous disease, were included in a therapeutic protocol based on the administration of anti-TNF-α monoclonal antibody (Infliximab). Sera and skin biopsies were collected before treatment and after 6 weeks of therapy. Tissues were kept in short term cultures and production soluble mediators such as TNF-α, MMP-9, MMP-2, VEGF and E-Selectin, which include angiogenic molecules associated to the development of plaque psoriasis, were measured in the culture supernatants by immunoenzymatic assays (ng/ml or pg/ml per mg of tissue). MMP-9 concentrations were also measured in the sera. The cutaneous activity of disease was evaluated by the Psoriasis Area and Severity Index (PASI). RESULTS: Clinical and laboratory assessment indicated that all but one patients had a significant improvement of the PASI score after three months of therapy. The clinical amelioration was associated to a significant decrease of MMP-9 (P = 0.017), TNF-α (P = 0.005) and E-selectin (P = 0.018) levels, spontaneously released by lesional biopsies before and after therapy. In addition, significant correlations were found between the PASI measurements and TNF-α (r(2 )= 0.33, P = 0.005), MMP-9 (r(2 )= 0.25, P = 0.017), E-selectin (r(2 )= 0.24, P = 0.018) production. MMP-9 levels were significantly correlated with those of TNF-α (r(2 )= 0.30, P = 0.008). A significant decrease of MMP-9 in the sera, associated to the clinical improvement was also found. CONCLUSION: Our findings show the existence of a direct relationship between MMP-9 and TNF-α production strongly suggesting that MMP-9 may play a key role in the skin inflammatory process in psoriasis. BioMed Central 2006-10-05 /pmc/articles/PMC1601955/ /pubmed/17022813 http://dx.doi.org/10.1186/1740-2557-3-5 Text en Copyright © 2006 Cordiali-Fei et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Cordiali-Fei, Paola
Trento, Elisabetta
D'Agosto, Giovanna
Bordignon, Valentina
Mussi, Anna
Ardigò, Marco
Mastroianni, Antonio
Vento, Antonella
Solivetti, Francesco
Berardesca, Enzo
Ensoli, Fabrizio
Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α
title Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α
title_full Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α
title_fullStr Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α
title_full_unstemmed Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α
title_short Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α
title_sort decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-tnf-α
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1601955/
https://www.ncbi.nlm.nih.gov/pubmed/17022813
http://dx.doi.org/10.1186/1740-2557-3-5
work_keys_str_mv AT cordialifeipaola decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT trentoelisabetta decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT dagostogiovanna decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT bordignonvalentina decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT mussianna decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT ardigomarco decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT mastroianniantonio decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT ventoantonella decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT solivettifrancesco decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT berardescaenzo decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa
AT ensolifabrizio decreasedlevelsofmetalloproteinase9andangiogenicfactorsinskinlesionsofpatientswithpsoriaticarthritisaftertherapywithantitnfa